Individual participant-level analysis of four randomized clinical trials examined therapeutic effects of blood pressure lowering on hierarchical kidney outcome using win statistics
Kidney International · 2026-07 · 110 (1) · 178-189
DOI: 10.1016/j.kint.2026.02.032 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Kidney International, 2026-07. Verfasst von Yezhou Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Health Statistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Antihypertensive Agents, Blood Pressure, Glomerular Filtration Rate, Hypertension. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
INTRODUCTION: Despite established cardiovascular benefits, the effects of intensive blood pressure (BP) lowering and specific agents on kidney function remain debated. Here, we assessed these effects using a validated hierarchical composite kidney endpoint (HCE) that prioritizes clinical severity. METHODS: This post hoc analysis used individual-level data from four large randomized clinical trials: SPRINT, ACCORD-BP, SHEP, and ALLHAT. The seven-tier HCE ranked components by clinical severity: all-cause mortality, kidney failure, estimated glomerular filtration rate (eGFR) under 15 mL/min/1.73m2, eGFR declines of 57%/50%/40% or more, and three-year total eGFR slope. We estimated Win Odds (WO) for all randomized participants, with missing outcomes handled as ties. RESULTS: A total of 61,248 participants were included with median follow-ups of 46 to 60 months across trials. Intensive BP treatment yielded unfavorable WO compared with standard treatment in SPRINT (WO, 0.61 [95% confidence interval, 0.58-0.64]) and ACCORD-BP (WO, 0.64 [0.59-0.68]. In SHEP, chlorthalidone was inferior to placebo (WO, 0.89 [0.84-0.95]). In ALLHAT, doxazosin (WO, 1.29 [1.25-1.33]) and amlodipine (WO, 1.38 [1.34-1.42]) outperformed chlorthalidone, while lisinopril was slightly less favorable (WO, 0.96 [0.93-0.98]). The eGFR slope component contributed over 50% to the win statistics across trials. Results were broadly consistent across subgroups and sensitivity analyses. CONCLUSIONS: Our hierarchical analysis indicated that intensive BP lowering and chlorthalidone were associated with less favorable mid-term eGFR trajectories. Driven largely by the eGFR slope, which represents a sensitive signal of kidney reserve depletion, our findings support monitoring kidney function to optimize the balance between cardiovascular protection and kidney preservation. TRIAL REGISTRATION: Registered at Clinicaltrials.gov with study numbers NCT01206062, NCT00000620, NCT00000514, and NCT00000542.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Health Statistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China.
- Department of Cardiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
- Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China.
- Department of Epidemiology and Health Statistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China; Department of Clinical Sciences, Liverpool School of Tropical Medicine,…
- Department of Epidemiology and Health Statistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China; Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaot…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, Y., Lyu, Y., Liu, Y., Zhang, J., Song, Z., Chen, K., Jiang, Z., Yan, H., Chen, T., & Li, C. (2026). Individual participant-level analysis of four randomized clinical trials examined therapeutic effects of blood pressure lowering on hierarchical kidney outcome using win statistics. Kidney International, 110(1), 178-189. https://doi.org/10.1016/j.kint.2026.02.032
Vancouver
Liu Y, Lyu Y, Liu Y, Zhang J, Song Z, Chen K, et al. Individual participant-level analysis of four randomized clinical trials examined therapeutic effects of blood pressure lowering on hierarchical kidney outcome using win statistics. Kidney International. 2026;110(1):178-189. doi:10.1016/j.kint.2026.02.032
BibTeX
@article{Liu2026,
author = {Liu, Yezhou and Lyu, Yizhen and Liu, Yamei and Zhang, Jiaheng and Song, Zhaojie and Chen, Kangyu and Jiang, Zhixin and Yan, Hong and Chen, Tao and Li, Chao},
title = {Individual participant-level analysis of four randomized clinical trials examined therapeutic effects of blood pressure lowering on hierarchical kidney outcome using win statistics},
journal = {Kidney International},
year = {2026},
volume = {110},
number = {1},
pages = {178--189},
doi = {10.1016/j.kint.2026.02.032}
}
EUVIMED